American Chemical Society (ACS Media Group & C&EN)

Gain an Edge in Pharma Services

C&EN delivers breaking pharmaceutical news and expert analysis, providing the hindsight, insight, and foresight needed to stay ahead.

Explore the latest in pharma at cen.acs.org and subscribe to our newsletter at https://cen.acs.org/new...

Connect with decision-makers, researchers, and innovators at ACS' premier chemistry events. Whether you're seeking high-impact visibility or meaningful in-person conversations, ACS exhibitor and sponsorship opportunities help organizations of every size stand out and make lasting impressions. 
...

Turn your expertise into high-impact content that generates qualified leads and builds trust with scientific decision-makers. Our turnkey lead generation programs leverage the powerful reach of ACS and C&EN to connect your content with highly engaged audiences. Formats include:
• Webinars • Wh...

Put your brand in front of influential scientists and decision-makers with targeted digital and print advertising solutions. Reach engaged chemical and life science audiences across C&EN, CAS Common Chemistry, and 90+ ACS journals while driving measurable awareness, engagement, and ROI.

...

Reaching a science-minded audience is hard. Creating effective messages for them is even harder. At ACS BrandLab, we help some of the world’s most innovative companies and institutions share their science via engaging and compelling custom content. 

Custom product opportunities incl...

Post your job where the industry's most qualified chemistry & engineering professionals go to advance their careers.

Learn more: https://chemistryjobs.acs.org/

Stay up to date with the latest scientific research, applications and technology with C&EN webinars. Register to join our upcoming live webinars or view on demand at any time.

https://cen.acs.org/collections/webinars.html

Read our featured white papers and eBooks. Download below at any time.
https://cen.acs.org/collections/whitepapers.html

CAS Custom ServicesSM partners with clients to identify and solve their scientific information challenges, delivering unique solutions that help them accelerate informed decision-making, mitigate risk, and uncover insights that drive success.  

https://www.brainshark.com/cas/pharmaK...

Connect with the world’s scientific knowledge and find the answers you need to advance your research. Combine the comprehensive information and powerful tools found in CAS SciFinder® and complete your research tasks with confidence.

https://www.brainshark.com/cas/SFDPCommBrochure

Chemical & Engineering News announces 2023 list of 10 chemistry start-ups to watch

Inside the 2026 Editorial Calendar, you’ll find everything you need to plan a high-impact year:
Audience & Reach Snapshot: Understand who you’ll connect with —and where2027 Editorial Themes: Organized by industry to align your messaging with what matters mostSponsorship Opportunities: Proven, high-visibility features designed for impactKey Dates & Deadlines: Stay ahead and execute with confidence

After several years of disruption and hard work, the pharmaceutical industry has dusted itself off and gotten back to business as usual. The number of drugs approved by the US Food and Drug Administration was certainly back up after 2022’s lean year, and drug companies with bulging coffers went on some high-profile spending sprees, snapping up biotechs to help their business development strategy as patent expirations loom.But what is business as usual? Our post-COVID-19 normality has changed our lives. In 2023, the pandemic-fueled pharma funding bubble also well and truly burst. Beyond the failure of Silicon Valley Bank and rising interest rates, investor sentiment seems to have cooled on biotechnology as a brand. Patients and industry executives are also watching to see how government-mandated price controls may begin affecting the pharma business.Both smaller biotechs and larger firms, such as Pfizer, Bayer, and GSK, ha...

With medicinal chemists’ innovative tools and techniques, it’s an exciting time to be building new drugs.

IN BRIEF
At one stage, small-molecule drugs seemed at risk of going out of fashion, as industry began to favor biotherapeutics. But over the past 10 years, small molecules have made it clear that they aren’t going away. New classes of molecules, such as proteolysis-targeting chimeras (PROTACs) and molecular glues, have people excited. So do technologies, such as machine learning and generative artificial intelligence, that are helping drive drug discovery. Today, drug hunters have more ambition to go after difficult targets and to use novel chemistry. And that makes it an exciting time for chemists.